The data that Gilead Sciences subsidiary Kite and Arcellx presented at the American Society of Hematology meeting for anitocabtagene autoleucel (anito-cel) were positive, but the question that remains is whether the apparent safety and tolerability advantage will be sufficient to give the BCMA-directed CAR-T cell therapy a competitive edge over the two players already on the market.
ASH: Gilead/Arcellx Point To Anito-Cel’s Safety, High-Risk Patient Advantages
Multiple myeloma patients in the iMMagine-1 study were less heavily pretreated than in the CARTITUDE-1 trial of Carvykti, but Gilead noted that more patients receiving anito-cel had high-risk features.
